Related Experiment Video

Updated: Jun 20, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

A novel class of cyclin-dependent kinase inhibitors identified by molecular docking act through a unique mechanism

Patrick Corsino1, Nicole Horenstein, David Ostrov

  • 1Department of Pharmacology and Therapeutics, University of Florida, Gainesville, Fliorida 32610-3633, USA.

The Journal of Biological Chemistry
|August 28, 2009
PubMed

Insights

Researchers discovered a new Cdk2 site, leading to novel inhibitors that cause cell cycle Cdk1, Cdk2, and Cdk4 protein aggregation, offering a new cancer treatment strategy.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Cyclin-dependent kinases (Cdks) are crucial regulators of the cell cycle and significant targets in cancer therapy.
  • Existing Cdk inhibitors primarily function as ATP-competitive agents, with limited success.
  • Cdks 1, 2, 4, and 6 are key cell cycle regulators, distinct from transcription-related Cdks like Cdk7 and Cdk9.

Purpose of the Study:

  • To identify novel therapeutic targets and inhibitors for cell cycle-regulated Cdks.
  • To explore non-ATP-competitive inhibition mechanisms for Cdk-targeted cancer therapy.

Main Methods:

  • High-throughput in silico screening to identify small molecules targeting a novel Cdk2 structural site.
  • Analysis of cytostatic effects, Cdk protein levels, Rb phosphorylation, and E2F-dependent gene expression.
  • Investigation of the mechanism of action, focusing on protein aggregation.

Main Results:

  • Identification of a novel, conserved structural site on Cdk2.
  • Small molecules targeting this site demonstrated cytostatic effects by reducing cell cycle Cdk protein levels.
  • Compounds induced cell cycle arrest, decreased Rb phosphorylation, and reduced E2F-dependent gene expression.

Conclusions:

  • A novel non-ATP-competitive inhibition strategy targeting cell cycle Cdks was identified.
  • The identified small molecules induce Cdk1, Cdk2, and Cdk4 protein aggregation as their primary mechanism of action.
  • This discovery opens new avenues for developing targeted cancer therapies by exploiting Cdk protein aggregation.

More Related Videos

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries08:49

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
Positive Regulator Molecules01:45

Positive Regulator Molecules

To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...